

FILE 'HOME' ENTERED AT 14:26:28 ON 29 JAN 2011

=> file biosis medline caplus wpids uspatfull  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.23 0.23

FILE 'BIOSIS' ENTERED AT 14:27:16 ON 29 JAN 2011  
Copyright (c) 2011 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 14:27:16 ON 29 JAN 2011

FILE 'CPLUS' ENTERED AT 14:27:16 ON 29 JAN 2011  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 14:27:16 ON 29 JAN 2011  
COPYRIGHT (C) 2011 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 14:27:16 ON 29 JAN 2011  
CA INDEXING COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

\*\*\* YOU HAVE NEW MAIL \*\*\*

=> s label? (4a) target and linker (4a) peptide bonds  
L1 9 LABEL? (4A) TARGET AND LINKER (4A) PEPTIDE BONDS

```
=> dup rem l1
PROCESSING COMPLETED FOR L1
L2          8 DUP REM L1 (1 DUPLICATE REMOVED)
```

=> d 12 bib abs 1-8

L2 ANSWER 1 OF 8 USPATFULL on STN  
AN 2010:363838 USPATFULL  
TI Multi-oligomeric or multi--polymeric compositions comprising labeled  
moieties and binding partners  
IN Rabbani, Elazar, New York, NY, UNITED STATES  
Stavrianopoulos, Jannis G., Bayshore, NY, UNITED STATES  
Donegan, James J., Long Beach, NY, UNITED STATES  
PA ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC., NEW YORK, NY, UNITED  
STATES (U.S. corporation)  
PI US 20100324268 A1 20101223  
AI US 2010-803355 A1 20100624 (12)  
RLI Division of Ser. No. US 2009-399393, filed on 6 Mar 2009, PENDING  
Division of Ser. No. US 2003-407818, filed on 3 Apr 2003, Pat. No. US  
7514551  
DT Utility  
FS APPLICATION  
LREP ENZO BIOCHEM, INC., 527 MADISON AVENUE (9TH FLOOR), NEW YORK, NY, 10022,  
US  
CLMN Number of Claims: 40  
ECL Exemplary Claim: 1-98  
DRWN 1 Drawing Page(s)  
LN.CNT 1182  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention provides multisignal labeling reagents and these  
reagents are useful for labeling biological molecules with multiple

manufacture of biomolecular probes and their use in detecting or amplifying analyte-specific moieties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 8 USPATFULL on STN  
AN 2009-288160 USPATFULL  
TI Multisignal Labeling Reagents, and Processes and Uses Therefor  
IN Rabbani, Elazar, New York, NY, UNITED STATES  
Stavrianopoulos, Jannis G., Bayshore, NY, UNITED STATES  
Donegan, James J., Long Beach, NY, UNITED STATES  
PI US 20090258374 A1 20091015  
AI US 2009-399393 A1 20090306 (12)  
RLI Division of Ser. No. US 2003-407818, filed on 3 Apr 2003, Pat. No. US 7514551  
DT Utility  
FS APPLICATION  
LREP THE WEBB LAW FIRM, P.C., 700 KOPPERS BUILDING, 436 SEVENTH AVENUE,  
PITTSBURGH, PA, 15219, US  
CLMN Number of Claims: 88  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 1395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides multisignal labeling reagents and these are useful in a number of biochemical applications, including the manufacture of biomolecular probes and their use in detecting or amplifying analyte-specific moieties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 8 WPIDS COPYRIGHT 2011 THOMSON REUTERS on STN DUPLICATE  
1  
AN 2004-727850 [200471] WPIDS  
CR 2009-P86761; 2010-Q65033  
TI Composition of multi signal labeling reagents, useful for detecting or quantifying analyte in specimen, has oligomer/polymer having labeled moieties, reactive groups and charged groups linked to oligomer/polymer  
DC B04; D16  
IN DONEGAN J J; RABBANI E; STAVRIANOPoulos J G  
PA (DONE-Z-I) DONEGAN J J; (ENZO-N) ENZO LIFE SCI INC; (RABB-I) RABBANI E;  
(STAV-I) STAVRIANOPoulos J G  
CYC 36  
PIA US 20040198971 A1 20041007 (200471)\* EN 20[1]  
CA 2461445 A1 20041003 (200471) EN  
JP 2004309486 A 20041104 (200472) JA 29  
EP 1489422 A2 20041222 (200501) EN  
JP 2008148709 A 20080703 (200845) JA 22  
US 7514551 B2 20090407 (200925) EN  
JP 4434819 B2 20100317 (201020) JA 26  
EP 1489422 A3 20100908 (201059) EN  
ADT US 20040198971 A1 US 2003-407818 20030403; US 7514551 B2 US 2003-407818  
20030403; CA 2461445 A1 CA 2004-2461445 20040319; JP 2004309486 A JP  
2004-110340 20040402; JP 2008148709 A Div Ex JP 2004-110340 20040402; JP  
4434819 B2 JP 2004-110340 20040402; EP 1489422 A2 EP 2004-8226 20040405;  
JP 2008148709 A JP 2008-5049 20080111; EP 1489422 A3 EP 2004-8226 20040405  
FDT JP 4434819 B2 Previous Publ JP 2004309486 A  
PRAI US 2003-407818 20030403  
AN 2004-727850 [200471] WPIDS  
CR 2009-P86761; 2010-Q65033  
AB US 20040198971 A1 UPAB: 20050707

NOVELTY - A composition (I) of matter comprising an oligomer or polymer having two or more labeled groups, where the label or labels are chemically linked to the oligomer or polymer, one or more reactive groups, and one or more charged groups where the charged groups are covalently linked to the oligomer or polymer or comprise part of the backbone of the oligomer or polymer, or any of their combination, is new.

DETAILED DESCRIPTION - A composition (I) of matter comprises

(a) an oligomer or polymer comprising two or more labeled moieties, where the label or labels are chemically linked to the oligomer or polymer, one or more reactive groups, and one or more charged groups where the charged groups are covalently linked to the oligomer or polymer or comprise part of the backbone of the oligomer or polymer, or any of their combination;

(b) a nucleic acid strand or a complex of two or more nucleic acid strands, where the strand or complex comprises one or more reactive groups and two or more labeled nucleotides or labeled nucleotide analogs;

(c) a nucleic acid strand or a complex of two or more nucleic acid strands, where the strand or complex comprises two or more labeled nucleotides or labeled nucleotide analogs, and one or more binding partners different from the labels;

(d) a compound having the formula (F1); or

(e) a compound having the formula (F2).

In formula (F1),

Q = a non-inherent charged group;

n = 1 or greater;

D = label;

m = 2 or greater;

R = one or more reactive group; and

P = oligomer or polymer.

In formula (F2),

D = label;

m = 2 or greater;

R = one or more reactive group; and

P = synthetic or chimeric oligomer or polymer, D or one or more of monomeric units of P has one or more charged groups.

INDEPENDENT CLAIMS are also included for the following:

(1) a composition (II) comprising a target molecule that has been labeled using (I); and

(2) a composition (III) prepared by a target labeling process comprising (i) providing a target for labeling, and a labeling reagent having the formula (F1) or (F2), (ii) reacting the target and the labeling reagent to form the composition having the formula (F3) or (F4).

L = linkage or linker between the oligomer or polymer and the target.

USE - (Ic) is useful for labeling a target molecule, which involves attaching or binding (Ic), to the target molecule chosen from peptides, proteins, antibodies, enzymes, enzyme substrates, ligands, hormones, receptors, antigens, haptens, lectins, avidin, streptavidin, toxins, carbohydrates, oligosaccharides, polysaccharides, ribonucleotides, deoxyribonucleotides, dideoxyribonucleotides, analogs of deoxynucleotides, ribonucleotides and dideoxynucleotides, modified deoxynucleotides, modified ribonucleotides, modified dideoxynucleotides, oligonucleotides and polynucleotides. (Ic) is useful for detecting or quantifying an analyte in a specimen, which involves:

(a) providing a specimen where an analyte is sought to be detected or quantified, (Ic) comprising a first non-hybridizing binding partner and an analyte specific moiety that comprises a second non-hybridizing binding partner, where the first and second binding partner comprises a binding pair;

(b) binding the analyte specific moiety to any analytes that may be

present in the specimen;

(c) binding the composition to any bound analyte specific moieties from step (b) through interactions between the first binding partners and the second binding partners; and

(d) measuring signal generation and thus detecting the presence or quantity of the analyte.

The first and the second binding partners are paired members chosen from biotin/avidin, biotin/streptavidin, antigen/antibody, hormone/hormone receptor, lectin/sugar, enzyme/enzyme substrate, enzyme/substrate analog, enzyme/enzyme inhibitor, co-factor/co-factor enzyme binding site, and chelator/chelate. The analyte specific moiety comprises an antibody or an antigen. The method further involves providing one or more unlabeled nucleic acids. The unlabeled nucleic acid comprises some or all of the sequences of the nucleic acid portion in (Ic). (Ic) is also useful for detecting or quantifying an analyte in a specimen, which involves (a) providing a specimen where an analyte is sought to be detected or quantified, (Ic) comprising a first non-hybridizing binding partner a linking moiety comprising a second non-hybridizing binding partner and a third non-hybridizing binding partner, an analyte specific moiety that comprises a fourth non-hybridizing binding partner, where the first and the second binding partner comprise a first binding pair, and the third and the fourth binding partner comprises a second binding pair, performing or carrying out at least one binding reaction by binding the analyte specific moiety to any analytes that may be present in the specimen, binding the third binding partner to the fourth binding partner, binding the first binding partner to the second binding partner, to form a complex that comprises the analyte, the analyte specific moiety, the linking moiety and (Ic), and detecting or quantifying the amount of signal generation in the complex. The step of performing or carrying out the binding reactions is performed or carried out sequentially or concomitantly. In the providing step, the first binding pair and the second binding pair comprise the same pair of binding partners. The analyte specific moiety comprises an antibody or an antigen. (II) or (III) is useful for detecting or quantifying an analyte, which involves providing (II) or (III), where the target is an analyte specific moiety, contacting the (II) or (III) with a specimen suspected of containing the analyte, and measuring the amount of (II) or (III) bound to analytes in the specimen to detect or quantify the analyte (all claimed).

ADVANTAGE - (I) detects or quantifies analyte with high sensitivity. In (I), the multiple labeled groups increases the amount of signal that is added to the analyte specific moiety, the presence of reactive groups enables attachment of the multiple labeled groups to a desirable target and the presence of charged group increases solubility.

L2 ANSWER 4 OF 8 USPATFULL on STN  
AN 2003:237907 USPATFULL  
TI Compositions and methods for the therapy and diagnosis of colon cancer  
IN King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Sechrist, Heather, Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)  
PI US 20030166064 A1 20030904  
AI US 2002-99926 A1 20020314 (10)  
RLI Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001,  
PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul  
2001, PENDING  
PRAI US 2001-302051P 20010629 (60)  
US 2001-279763P 20010328 (60)

US 2000-223283P 20000803 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,  
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 8531

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 8 USPATFULL on STN  
AN 2003:106233 USPATFULL

TI Compositions and methods for the therapy and diagnosis of pancreatic cancer

IN Benson, Darin R., Seattle, WA, UNITED STATES  
Kalos, Michael D., Seattle, WA, UNITED STATES  
Lodes, Michael J., Seattle, WA, UNITED STATES  
Persing, David H., Redmond, WA, UNITED STATES  
Hepler, William T., Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 20030073144 AI 20030417

AI US 2002-60036 AI 20020130 (10)

PRAI US 2001-333626P 20011127 (60)  
US 2001-305484P 20010712 (60)  
US 2001-265305P 20010130 (60)  
US 2001-267568P 20010209 (60)  
US 2001-313999P 20010820 (60)  
US 2001-291631P 20010516 (60)  
US 2001-287112P 20010428 (60)  
US 2001-278651P 20010321 (60)  
US 2001-265682P 20010131 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,  
SEATTLE, WA, 98104-7092

CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 8 USPATFULL on STN  
AN 2003:209861 USPATFULL  
TI HLA class I A2 tumor associated antigen peptides and vaccine compositions  
IN Fikes, John D., San Diego, CA, United States  
Sette, Alessandro, La Jolla, CA, United States  
Sidney, John, San Diego, CA, United States  
Southwood, Scott, Santee, CA, United States  
Celis, Esteban, Rochester, MN, United States  
Keogh, Elissa A., San Diego, CA, United States  
Chesnut, Robert, Cardiff-by-the-Sea, CA, United States  
PA Epimmune Inc., San Diego, CA, United States (U.S. corporation)  
PI US 6602510 B1 20030805  
AI US 2000-543608 20000405 (9)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Schwadron, Ronald B.  
LREP Sterne, Kessler, Goldstein & Fox P.L.C.  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)  
LN.CNT 3397

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition or vaccine composition comprising eight isolated epitopes consisting of YLSGANLNV (SEQ. ID. NO: 1), IMIGVLVGV (SEQ. ID. NO: 2), KLBPVQLNV (SEQ. ID. NO: 3), SMPGGTRV (SEQ. ID. NO: 4), KVAEVHFL (SEQ. ID. NO: 5), YLQLVFGIEV (SEQ. ID. NO: 6), RLLQETELV (SEQ. ID. NO: 7), and, VVLGVVFGI (SEQ. ID. NO: 8).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 8 USPATFULL on STN  
AN 2002:272801 USPATFULL  
TI Compositions and methods for the therapy and diagnosis of colon cancer  
IN Stolk, John A., Bothell, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Chenault, Ruth A., Seattle, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)  
PI US 2002150922 A1 20021017  
AI US 2001-998598 A1 20011116 (9)  
PRAI US 2001-304037P 20010710 (60)  
US 2001-279670P 20010328 (60)  
US 2001-267011P 20010206 (60)  
US 2000-252222P 20001120 (60)

DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 9233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are

specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 8 USPATFULL on STN  
AN 2002:243051 USPATFULL  
TI Compositions and methods for the therapy and diagnosis of ovarian cancer  
IN Algate, Paul A., Issaquah, WA, UNITED STATES  
Jones, Robert, Seattle, WA, UNITED STATES  
Harlocker, Susan L., Seattle, WA, UNITED STATES  
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)  
PI US 20020132237 A1 20020919  
AI US 2001-867701 A1 20010529 (9)  
PRAI US 2000-207484P 20000526 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,  
SEATTLE, WA, 98104-7092  
CLMN Number of Claims: 11  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 25718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>